Navigation Links
TGen researcher awarded American Cancer Society fellowship

PHOENIX, Ariz. May 12, 2010 Dr. James Bogenberger has been awarded a 3-year, $150,000 postdoctoral fellowship by the American Cancer Society to research acute myeloid leukemia at the Translational Genomics Research Institute (TGen).

Acute myeloid leukemia (AML), the most common and deadliest acute adult leukemia, is a malignancy in granulocytes or monocytes, the body's white blood cells that battle infections.

Dr. Bogenberger's project, Identifying therapeutic targets that sensitize AML to epigenetic therapies, is under the guidance of Dr. Raoul Tibes, an Associate Investigator in TGen's Clinical Translational Research Division and Director of the Hematological Malignancies Program for TGen Clinical Research Service at Scottsdale Healthcare.

Dr. Bogenberger is a member of TGen's Leukemia Research Team, led by Dr. Tibes, which is working to translate state-of-the-art biomedical research into novel targeted therapy approaches for leukemia patients in Arizona. Dr. Bogenberger's fellowship project, which starts July 1, is a collaboration between TGen and a research team at the Mayo Clinic, led by Dr. A. Keith Stewart.

"We are hopeful about the prospects of further investigation and the potential of translating our findings into the clinic,'' said Dr. Bogenberger, who received his doctorate in Cell and Molecular Biology from Colorado State University. "We look forward to demonstrating the merit of our work."

A congratulatory letter from the American Cancer Society to Dr. Bogenberger said, "Your selection resulted from a very rigorous review process intended to fund only the best science and the best scientists and professionals."

AML, which is neither contagious nor inherited, develops through a defect in the immature cells of bone marrow. Although the exact cause is unknown, AML has been linked to prior chemotherapy exposure, benzene exposure and cigarette smoking. Fewer than 10 percent of patients live beyond three years, and there is an urgent need to improve treatment of AML.

Therapeutic drugs that target single cellular processes have shown limited impact in fighting this type of cancer. Because AML results from a progression of multiple cellular processes, Dr. Bogenberger's project proposes to attack the cancer by identifying targets to inhibit in combination with drugs already approved by the U.S. Food and Drug Administration 5-Azacytidine and suberoylanilide hydroxamic acid (SAHA).

His fellowship project will use cutting-edge methodologies to systematically look for genes that, when silenced, "increase the anti-leukemic potency" of these epigenetic therapies, according to the ACS project summary.

Dr. Bogenberger's ACS award will allow him to build on previous research into AML he has conducted since joining TGen in October 2008.

"Since James joined the lab, he has done excellent work and actively contributed to move projects forward, and we are initiating clinical trials as we speak from results that have come out of these projects," Dr. Tibes said. "This fellowship is well deserved and I congratulate him."


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
6. U of MN researchers discover noninvasive diagnostic tool for brain diseases
7. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
8. Researchers discover new strategies for antibiotic resistance
9. Researchers find new taste in fruit flies: carbonated water
10. Binghamton University researchers investigate evolving malaria resistance
11. Antioxidant to retard wrinkles discovered by Hebrew University researcher
Post Your Comments:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
(Date:11/24/2015)... Worcester, Mass. (PRWEB) , ... November 24, 2015 ... ... need to maintain healthy metabolism. But unless it is bound to proteins, copper ... Institutes of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a ...
Breaking Biology Technology: